Cryptococcal meningitis is an infection of the lining of the brain and spinal cord. The fungus that causes this infection is found in soil. The risk is highest when CD4 cell counts are below 100. You can get it by breathing in dust. Symptoms include headache, nausea, fever, fatigue, irritability, sensitivity to light, stiff neck, change in mental state, and hallucinations.
The results of the ACTA trial were presented at the 9th IAS Conference on HIV Science held in Paris from 23 to 26 July 2017. Professor Thomas Harrison and his colleagues at St George's University of London, the Institut Pasteur in Paris, Paris Descartes University (Hôpital Necker-Enfants Malades), the ANRS site in Cameroon, and the MRC sites in Malawi, Tanzania, and Zambia show in this trial that new therapeutic regimens are of benefit in HIV-infected patients with cryptococcal meningitis.
Large populations of potentially deadly cryptococcal fungi have been found on woody debris collected from old trees in two public areas in the center of Cape Town and the Northern Cape, South Africa.
A study published in the New England Journal of Medicine on 20th July 2017 suggests that a cocktail of drugs, if provided at the beginning of the HIV therapy, can save over 10,000 lives per year. HIV, which is often diagnosed late, leaves people vulnerable to other diseases by ravaging the immune system.
International HIV experts have reported approximately 250,000 fungal meningitis cases annually, in the AIDS report, sub-Saharan Africa contributing 73% of cases. Cryptococcus fungus causes fungal meningitis and usually affects individuals who are above 35 years old, affecting the tissues covering the brain and the spinal cord
Estimates never before attempted, show the number of people affected by serious fungal diseases in 14 of the worst affected countries across the globe have just been published.
New concepts of infectious disease are evolving with the realization that pathogens are key players in the development of progressive chronic diseases that originally were not thought to be infectious. Infection is well-known to be associated with numerous neurological diseases for which...
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis
Cryptococcus is a fungus found in the environment throughout the world that is able to cause disease in humans. While most fungal pathogens don’t receive as much press as their bacterial or viral counterparts, they can be just as deadly.
Scientists at Duke Medicine are using transparent fish to watch in real time as Cryptococcal meningitis takes over the brain. The resulting images are worthy of a sci-fi movie teaser, but could be valuable in disrupting the real, crippling brain infection that kills more than 600,000 people worldwide each year.
The fungus Cryptococcus causes meningitis, a brain disease that kills about 1 million people each year — mainly those with impaired immune systems due to AIDS, cancer treatment or an organ transplant.
A new approach to care for patients with advanced HIV in Tanzania and Zambia, combining community support and screening for a type of meningitis, has reduced deaths by 28%.
A leading microbiologist has warned of the increasing threat that killer fungi poses to humans and the environment.
In a remarkable series of experiments on a fungus that causes cryptococcal meningitis, a deadly infection of the membranes that cover the spinal cord and brain, investigators at UC Davis have isolated a protein that appears to be responsible for the fungus' ability to cross from the bloodstream into the brain.
Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio-, the online open-access journal of the American Society for Microbiology (ASM.)
Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.
The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.
A new rapid test to diagnose melioidosis, a difficult infection to treat - and classified as a biothreat by the Centers for Disease Control and Prevention - is being optimized and tested by University of Nevada School of Medicine researcher David AuCoin.
New research conducted by biologists at Texas A&M University suggests that ZOLOFT, one of the most widely prescribed antidepressants in the world, also packs a potential preventative bonus - potent mechanisms capable of inhibiting deadly fungal infections.
Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.
Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.